<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677088</url>
  </required_header>
  <id_info>
    <org_study_id>LTCR-HCC-2-2</org_study_id>
    <nct_id>NCT04677088</nct_id>
  </id_info>
  <brief_title>TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation</brief_title>
  <official_title>Phase I Study of T Cell Receptor-Redirected T Cells With Recurrent HBV Treatment in Patients-Related Hepatocellular Carcinoma in Post Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaoshun He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lion TCR Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm and open-label study to assess the safety, tolerability and primary&#xD;
      efficacy of the HBV specific T cell receptor (HBV/TCR) redirected T cell in patients with&#xD;
      recurrent Hepatitis B virus (HBV) related hepatocellular carcinoma post liver&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation of the TCR-T treatment</measure>
    <time_frame>Start of Treatment until 28 days post last dose</time_frame>
    <description>Incidence of adverse events/serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Start of treatment until disease progression, and subsequent follow up up to 24 months post treatment.</time_frame>
    <description>Tumour assessment will be according to RECIST v1.1. This is based on percentage of participants with Complete Response (CR) and Partial Response (PR) according to RECIST v1.1 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Start of treatment until disease progression, and at 6-month and 1-year.</time_frame>
    <description>1-year PFS is measured by the number of patients with stable disease after 1 year, using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Start of treatment until disease progression, and at 6-month and 1-year.</time_frame>
    <description>OS is defined as the time from randomisation until death by any cause. Participants will be followed up for survival follow up for two years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Recurrent Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HBV/ TCR T cell infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous T cells with HBV antigen-specific TCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCR-T cells</intervention_name>
    <description>Patients will receive 1 x 10^4 cells/kg to 5 x 10^6 cells/kg bodyweight of TCR redirected T cells by IV infusion.</description>
    <arm_group_label>HBV/ TCR T cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis as hepatocellular carcinoma (HCC).&#xD;
&#xD;
          2. Recurrent locally advanced and/or metastatic hepatocellular carcinoma (HCC) post liver&#xD;
             transplantation.&#xD;
&#xD;
          3. Seropositive for hepatitis B surface antigen, or presence of HBV DNA or HBV RNA.&#xD;
&#xD;
          4. HLA profile matching with HLA-class I restriction element of the available T cell&#xD;
             receptors.&#xD;
&#xD;
          5. ECOG performance status ≤ 2.&#xD;
&#xD;
          6. Laboratory criteria:&#xD;
&#xD;
               1. Liver function: ALT and AST ≤ 5 of upper limit of normal (ULN), TBIL ≤ 3 x ULN.&#xD;
&#xD;
               2. Neutrophil cell number ≥1.5×10^9/L.&#xD;
&#xD;
               3. Platelet count ≥100×10^9/L.&#xD;
&#xD;
          7. Ability to provide informed consent.&#xD;
&#xD;
          8. Willing and able to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Second primary malignancy that is clinically detectable at the time of consideration&#xD;
             for study enrolment.&#xD;
&#xD;
          2. Likelihood to require steroid treatment during the period of the clinical trial.&#xD;
&#xD;
          3. Lack of peripheral venous or central venous access or any condition that would&#xD;
             interfere with drug administration or collection of study samples.&#xD;
&#xD;
          4. Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          5. Administration of any other cell therapy, including NK, CIK, DC, CTL, CAR- T, stem&#xD;
             cells or combined therapy of the kind within 28 days prior to start of treatment.&#xD;
&#xD;
          6. Any condition that is unstable or which could jeopardise the safety of the patient and&#xD;
             his/her compliance in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun-Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, Tan HK, Kumar R, Irani FG, Ho ZZ, Zhang Q, Guccione E, Wai LE, Koh S, Hwang W, Chow WC, Bertoletti A. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology. 2019 May;156(6):1862-1876.e9. doi: 10.1053/j.gastro.2019.01.251. Epub 2019 Jan 31.</citation>
    <PMID>30711630</PMID>
  </reference>
  <reference>
    <citation>Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol. 2015 Feb;62(2):486-91. doi: 10.1016/j.jhep.2014.10.001. Epub 2014 Oct 13.</citation>
    <PMID>25308176</PMID>
  </reference>
  <reference>
    <citation>Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23.</citation>
    <PMID>21145860</PMID>
  </reference>
  <reference>
    <citation>Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43.</citation>
    <PMID>23941866</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xiaoshun He</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

